US Pharma MarketingBluebird Bio was a dark biotech morality tale when David Meek bought it. He says the new company, Genetix, is already making money. research Vaccines Congress Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Biotech A year after distressed buyout, what’s become of Bluebird Bio? CEO David…
David Meek bought Bluebird Bio last year for the pharma industry equivalent of loose change.
The company was on the brink of bankruptcy. In 12 months, he says, it’s been transformed.
In a swaggering interview, one of the first he’s given since the deal, Meek lambasted competitors and claimed the company would dominate the market for sickle cell disease gene therapies for years to come. By 2030, he said the company — now rebranded as Genetix — would be treating 1,000 patients per year.
Source: STAT News Pharma